$12.12
-0.88-6.74%
Last update: Nov 12, 4:05 PM
4D Molecular Therapeutics Inc
FDMTNASDAQ
4D Molecular Therapeutics rose 10.4% from $10.97 to $12.12, behind the S&P 500's +11.2%. Its worst day was Dec 17 (−20.1%), and its low came Jan 6 at $7.19.
Nov 12, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with
−20.1%, the year's worst day · S&P 500 −1.1%
Story events cover the past 12 months · Times ET
4D Molecular Therapeutics closed at its lowest level of the year, 34.5% below where the year started.
−1.5% · S&P 500 +0.6%
4D Molecular Therapeutics shares fell 13.1%, while the S&P 500 rose 0.3%.
−13.1% · S&P 500 +0.3%
EPS of $0.43 beat the $-0.53 estimate on $85.1M revenue (est. $32.2M).
+4.9% · S&P 500 −0.5%
EPS of $-1.01 missed the $-0.99 estimate on $3.0M revenue (est. $2.8M).
+2.1% · S&P 500 +0.8%
4D Molecular Therapeutics shares fell 13.7%, while the S&P 500 fell 2.6%.
−13.7% · S&P 500 −2.6%
EPS of $-1.04 missed the $-1.02 estimate on $3.8M revenue (est. $2.5M).
+4.6% · S&P 500 −0.2%
EPS of $-1.08 missed the $-1.05 estimate on $4.1M revenue (est. $3.2M).
−6.7%
Where it ended: a close of $12.12 on Nov 12, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-1.05, revenue est. $3.2M).
Nothing in the past 12 months.
All FDMT dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for FDMT and SPY from Benzinga historical bars. Not investment advice.
